UPDATE 1-Roche pushes late-comer Tecentriq as new liver cancer option
October 21, 2019 at 04:16 AM EDT
Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals.
